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ABSTRACT 
Objective: assessment of acute, subchronic and chronic toxicity of pegylated gold nanorods (PEG-gold NRs) in Wistar rats of both sex in three 
routes of administration {intravenous (IV), intramuscular (IM) and subcutaneous (SC)}.  
Methods: in the acute toxicity study; PEG-gold NRs were injected once by three different routes, blood and tissue samples were collected after 14 d. 
In the subchronic and chronic studies; PEG-gold NRs were injected via three different routes, at 0.225, 0.45 and 0.9 mg/kg, once daily for 5 
consecutive days, followed by a 23-day recovery period, for three and six months in the subchronic and chronic toxicity studies, respectively. 
Hematology, urinalysis, biochemical and histopathological examinations were conducted at the end of each study.  
Results: acute toxicity showed a significant decrease in serum triglycerides and cholesterol levels after single IV, IM and SC injection of PEG-gold 
NRs, while serum creatinine was significantly increased after IV and IM injection. Subchronic results revealed a significant decrease in serum 
triglycerides and cholesterol levels. The chronic study showed a significant decrease in serum triglycerides, sodium levels, total leukocytes count 
and significant increase in serum creatinine after IV injection. IM injection resulted in significant decrease in serum alkaline phosphatase, 
triglycerides, cholesterol, sodium levels and total leukocytes count. SC injection resulted in significant decrease in serum triglycerides, glucose, red 
blood cell count with increased creatinine and hematocrit.  
Conclusion: PEG-gold NRs at the three examined doses is apparently safe since no serious signs of toxicity were detected. IM and SC routes of 
injection were irritating, so we recommend the IV route. 
Keywords: Pegylated gold nanorods, Intravenous, Intramuscular, Subcutaneous, Acute, Subchronic, Chronic toxicity. 
 
INTRODUCTION 
Nanotechnology is a relatively new field of technology that takes 
advantage of the unique properties of particles in the “nano” size 
range. Nanotechnology is now a major part of almost every industry. 
On the other hand, nanomedicine is the biomedical application of 
nanotechnology[1, 2]. 
Gold nanomaterials have great application due to a straightforward 
synthesis, stability, and ease of incorporation of functional groups 
for targeting capabilities, as in gene and protein delivery, biological 
imaging, cancer treatments, and in implants [3].  
Studies have suggested that the size, surface charge, and shape are key 
factors related to potential toxicity of medicinal gold complexes [4].  
Nanoparticles are comparable in size to many biological molecules 
and subcellular components, which should bring about interesting 
interactions with cellular compartments and biological systems. 
These interactions could be beneficial, or could easily result in an 
adverse response and then toxicity [5, 6]. 
Proteins bind the surfaces of nanoparticles, and biological materials, 
in general, immediately upon introduction of the materials into a 
physiological environment. The further biological response of the 
body is influenced by the nanoparticle–protein complex. Protein 
binding is one of the key elements that affect biodistribution of the 
nanoparticles throughout the body [7]. This binding can result in the 
original effective surface charge of nanoparticles flipping from 
cationic to anionic or vice versa. This layer of more or less tightly 
bound proteins adsorbed to the surface of the nanoparticles has 
recently been identified as the protein “corona” [8, 9]. 
The nature of adsorbed biomolecules are of great importance since 
they represent the observable layer around the nanoparticles that 
the cell “sees” and interacts with, and thus influence the toxicity, 
cellular uptake, pharmacokinetics, and immunogenicity of these 
nanomaterials [6, 8]. 
Numerous studies have demonstrated that undesired removal of 
particles in organs that contain large numbers of macrophages such as 
the liver, spleen, and lung can be delayed by coating the particles with 
shielding molecules such as poly (ethylene glycol), but such strategies 
appear to impact negatively on the targeting specificity [10]. 
The majority of nanotoxicity studies have focused on health effects 
of exposure to ultrafine particles by inhalation, contact through the 
skin, or ingestion [4]. As nanomaterials expand as therapeutics and 
as diagnostic tools, parenteral administration of engineered nano-
materials should also be recognized as a critical aspect for toxicity 
consideration [4, 6].  
Therefore, this study aims to evaluate the systemic toxicity of 
pegylated gold nanorods (PEG-Gold NRs) administered to rats 
parenterally via intravenous (IV), intramuscular (IM) and 
subcutaneous (SC) injection. 
MATERIALS AND METHODS 
Materials 
Chemicals, Diagnostic kits, and equipment 
- Cetyltrimethyl ammonium bromide (CTAB) and Sodium 
borohydride (99%) were purchased from Merck chemicals 
(Germany) and LOBA Chemie (India), respectively. 
- Silver nitrate and L-ascorbic acid were purchased from Sigma-
Aldrich, Germany. All the reagents were an analytical grade and used 
without further purification. Deionized water (18 MΩ) was used in 
all experiments. 
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- Determination of serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) according to Reitman and 
Frankel[11], total bilirubin according to Malloy and Evelyn[12], 
Gama-glutamyl transferase (Gamma-GT) according to Szasz [13], 
alkaline phosphatase (ALP) according to Belfield and Goldberg[14]. 
Serum Albumin according to Bartholomew and Delaney [15] and 
protein according to Gornall et al. [16]. Calcium was done according 
to Gindler and King [17], phosphorus according to El-Merzabani et 
al.[18] and sodium according to Trinder [19]. Cholesterol according 
to Allan and Dawson[20] and triglycerides according to Fossati and 
Prencipe[21], and Trinder [22]. Urea and Creatinine according to 
Wills and Savory[23] and Kroll et al. [24], respectively. Glucose 
according to Trinder[22]. All commercial kits were obtained from 
Biodiagnostic Co., Egypt. 
- Mindray's® automatic hematology analyzer was used for 
estimation of hematological parameters (complete blood picture). 
- Urine analysis was carried out using urinalysis reagent strips 
(TECO Diagnostics, USA). 
Methods 
Synthesis and pegylation of gold nanorods 
The nanorods were synthesized according to the seed-mediated 
growth method [25] as follow:- 
Seed solution 
CTAB solution (5 ml, 0.20 M) was mixed with HAuCl4 (5 ml, 0.0005 
M) under vigorous stirring. Next, 0.6 ml of ice-cold 0.01 M NaBH4 
was added to the solution. The solution turned brownish yellow 
immediately after adding NaBH4, indicating particle formation. The 
particles in this solution were used as seeds. Vigorous stirring of the 
seed solution was continued for 2 min. After the solution was 
stirred, it was kept at 25 °C. 
Growth of NRs with plasmon bands less than 850n 
In a clean test tube, 10 ml of gentle mixing growth solution, 
containing (5 ml, 0.20 M) of CTAB and (5 ml, 0.001M) of HauClR4R, was 
mixed with 0.35 ml of 0.004 M AgNOR3R solution at 25 °C. To this 
solution, 5 ml of 1M HCl was added, and after gentle mixing of the 
solution 70 µl of 0.0788 M ascorbic acid was added. Ascorbic acid as 
a mild reducing agent changes the growth solution from dark yellow 
to colorless. It is worth noting that the growth solutions above are 
identical except for their silver ion content. The final step was the 
addition of 12 µl of the seed solution to the growth solution at 27-30 
°C. The color of the solution gradually changed within 10-20  min. 
For longer NRs, the color change takes place more slowly. The 
temperature of the growth medium was kept constant at 27-30 °C in 
all the experiments. This pathway produces pure NR solutions with 
aspect ratios (4.6) and a longitudinal plasmon absorption maximum 
at 800 nm. 
Gold nanorods solutions were centrifuged twice at 14,000 rpm for 
15 min and redispersed in deionized water to remove excess CTAB 
molecules. mPEG-SH (MW5000) was added to the 1~ nM colloidal 
nanorod solution at a final concentration of 10 mM. Rods were 
stirred overnight and centrifuged at 14000 rpm for 15 min and 
redispersed in deionized water to remove non-specifically bound 
PEG molecules. The pegylated gold nanorods were again centrifuged 
at 14,000 rpm for 15 min, sterile filtered and re-dispersed in 10 mM 
phosphate-buffered saline (PBS, Mediatech) to the desired optical 
density at 800 nm. Extinction spectra of the pegylated nanorod 
saline suspensions showed no peak shift, broadening, or reduction 
over a 1-week period prior to injection [26].  
Animals 
The experiment began with Adult albino rats, Wister strain, six-
week-old weighing ~150-180 g, of both sex were used throughout 
the study. They were obtained from the Animal House Colony of the 
National Research Center (Dokki, Giza, Egypt) and were housed 
under conventional laboratory conditions throughout the period of 
experiments. Animal procedures were performed in accordance 
with the Ethics Committee of the National Research Centre and 
followed the recommendations of the National Institutes of Health 
Guide for Care and Use of Laboratory Animals [27].  
Experimental 
Instrumentation 
Absorption spectra of the prepared solutions of Nanorods (NRs) 
were measured in the range of 1000-200 nm using Jasco 570 
ultraviolet-visible (UV-VIS)-NIR spectrophotometer. 
The morphology of gold NRs was studied by Transmission Electron 
Microscope (JEOL-JEM 2010) operated at 200 kV accelerating 
voltage. The preparation of TEM grid, the transmission electron 
microscope (TEM) image was taken after separating the surfactant 
from the metal particles by centrifugation. Typically 1 ml of the 
sample was centrifuged for 10 min at a speed of 14000 rpm. The 
upper part of the colorless solution was removed and the solid 
portion was redispersed in 1 ml of water; 2 µl of this redispersed 
particle suspension was placed on a carbon-coated copper grid and 
dried at room temperature. 
Experimental design 
Acute toxicity study of gold nanorods in normal rats 
determined according to guidelines of Food and Drug Administration 
(FDA) and Environmental Protection Agency (EPA) [28].  
Animals were acclimated for 5 d prior to test and fasting overnight 
prior to dosing. Rats were divided into 4 main groups. In each group, 
there were 2 subgroups of 6 males and 6 females that were treated 
as follows, rats of the control group were injected once with saline. 
The other three groups of rats were injected with a single dose of 0.9 
mg/kg. PEG-Gold NRs by intravenous (IV), intramuscular (IM) and 
subcutaneous (SC) routes. 
Observation of rats for 14 d, for any changes in the skin and fur, 
respiratory, circulatory, autonomic, and central nervous systems, 
and in somatomotor activity and behavior pattern. Particular 
observation for tremors, convulsions, salivation, diarrhea, lethargy, 
sleep and coma were done.  
Blood was collected from the retro-orbital venous plexus of 
anesthetized rats after 14 d for hematology and blood chemistry 
analysis. Mindray's® automatic hematology analyzer was used for 
estimation of hematological parameters (complete blood picture). 
After that rats were sacrificed by cervical dislocation. Gross 
necropsy for the heart, liver, spleen and kidneys and wet organ 
weight was recorded immediately after section to avoid drying, and 
relative organs weight (ROW) was calculated according to 
Chavalittumrong et al. [29].  
Histopathological examination for all target tissues (liver, kidneys, and 
spleen) of the control and treated groups was performed. Organ 
tissues were fixed in 10% formalin and processed for paraffin sections 
of 4 um thick. Then stained by hematoxylin and eosin (H & E). 
Subchronic and chronic toxicity studies of gold nanorods in 
normal rats 
Experimental procedures were performed in accordance with the 
recommendations of the proper care and use of laboratory animals 
and in accordance with the extensive protocol developed by the 
Laboratory of Toxicology of the National Cancer Institute (NCI). This 
protocol was offered as a model for preclinical evaluation of 
anticancer agents and was accepted by The Food and Drug 
Administration [30]. 
PEG-gold NRs was injected at three dose levels of 0.225, 0.45, 0.9 
mg/kg which equal to (75, 150 and 300 ppm) respectively through 
IV, IM and SC routes. Injection for 5 consecutive days followed by 23 
d recovery period and this treatment regimen was repeated for a 
total of three {for subchronic toxicity study} and six cycles{for sub-
chronic toxicity study} [31]. 
Males and females rats ̍  were acclimated for at least 5 d prior to test. 
Then rats were divided into 12 main groups of 20 rats each for each 
study {subchronic "3 mo" or chronic study "6 mo"} as follows: -three 
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control groups of rats were injected with saline by IV, IM, and SC. 
Nine groups of rats were injected with PEG-gold NRs 0.225, 0.45 and 
0.9 mg/kg by IV, IM and SC. Each animal group was comprised of 2 
subgroups of 10 male and 10 female rats.  
Daily rats' observation for occurrence of morbidity and mortality 
and for any change appears in the skin and fur, respiratory rats, 
central nervous system disturbance as { tremors, convulsions, 
lethargy, sleep disturbance, coma} and behavioral. Blood was 
collected from the retro-orbital venous plexus of an anesthetized 
animal, at 1 interim point and at the end of each experiment for 
hematology and blood chemistry analysis.  
Twenty-four hours urine samples were collected from rats and were 
directly visualized for any abnormal color, odor and turbidity. 
Urinalysis reagent strips were used for determination of urine pH, 
specific gravity and for detection of blood, bilirubin, urobilinogen, 
ketone, glucose, protein, nitrite and leukocytes.  
Rats were sacrificed at the end of the experiment. Gross necropsy 
and weighing of the heart, spleen, liver, kidneys, brain, testes, 
epididymis, prostate, ovaries and uterus were done immediately 
post mortem to avoid drying, then were placed in formalin 10%. 
Histopathological examination for target tissues {liver, kidneys, and 
spleen} was performed. 
Statistical analysis 
Data obtained from the present study were analyzed using one-way 
ANOVA followed by Dunnett's multiple comparison test using SPSS 
statistics 17.0, Chicago, USA. The results were expressed as mean±SEM. 
RESULTS 
Transmission electron microscopy (TEM) data 
Transmission electron microscope (TEM) image of NRs prepared are 
shown in fig. (1). 
 
  
Fig. 1: TEM image of gold NRs with plasmon band energies at 800 nm 
 
From this image, it is clear that a uniform shape of NRs with regular 
distribution were formed. The aspect ratio of a shape is defined as 
the length of the major axis divided by the width of the minor axis 
[32]. The length of rods (60±5 nm) and aspect ratio is (4.6). The 4.6 
aspect ratio rods were too close in size to the spheres to allow for 
sufficient separation. The formation mechanism of NRs depend on the 
template; we have observed that using concentrated CTAB solution 
enhances the rod yield. Concentrated CTAB has a tendency to form 
elongated rod-like micellar structures that possibly assist in rod 
formation, as well as stabilizing the rods. This template was used 
earlier for the electrochemical synthesis of gold nanorods, and the 
aspect ratio was controlled by introducing AgP+Pions or a more 
hydrophobic co-surfactant (compared to CTAB). The enhanced growth 
rate in the presence of seed (possibly diffusional growth) and the rod-
like micellar template contribute to the rod formation [33]. 
UV-Visible spectra for gold NRs 
The optical properties of metallic nanoparticles depend on shape. 
This is due to the absorption of visible light both along the length of 
the nanorod {the longitudinal plasmon band}and along the width of 
the nanorod (the transverse plasmon band) [3]. The ultraviolet-
visible (UV–VIS) spectra of the NRs colloids are shown in fig. (2).  
In this figure, it was found that, the surface plasmon absorption of 
gold nanorods have two bands, a strong long-wavelength band (800 
nm) due to the longitudinal oscillation of electrons and a weak 
short-wavelength band around 514 nm due to the transverse 
electronic oscillation [33, 34]. 
Acute toxicity 
Rats injected with pegylated gold nanorods (PEG-Gold NRs) in dose (0.9 
mg/kg) via intravenous and intramuscular routes showed mild 
symptoms of toxicity. While that injected with gold NRs subcutaneously 
showed no signs of toxicity throughout the whole duration of 2 w. 
 
Fig. 2: UV-Visible-NIR absorption spectra of the gold NRs 
prepared using single surfactant mixtures 
 
Weight loss, hair loss, and slight aggression were the signs of toxicity 
detected within groups. The onset of toxicity was faster in males 
compared to counterpart female groups.  
Serum triglycerides and cholesterol levels were significantly 
decreased in both male and female rats after single intravenous, 
intramuscular and subcutaneous injection of gold nanorods, 
compared to control rats. While, creatinine level was significantly 
increased in rat groups receiving gold nanorods via intravenous or 
intramuscular routes in both sex (table 1). No significant 
organomegaly or gross pathological findings were detected after 
single intravenous, intramuscular and subcutaneous injection of 
gold nanorods, except for slight increase in liver weight in rats 
subcutaneously injected gold nanorods in both sexes (table Ι in 
supplementary data). 
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Table 1: Acute toxicity effect of single intravenous, intramuscular and subcutaneous injection of PEG-Gold NRs (0.9 mg/kg); on some 
serum biochemical parameters in rats of both sex (n=6) 
 Control IV IM SC 
Male Female Male Female Male Female Male Female 
ALT (U/ml) 56.9±1.17 61.1±3.69 59.2±1.59 56.4±0.53 58.6±1.07 57.8±0.62 54.9±0.80 58.9±2.46 
AST (U/ml) 85.1±1.81 94.6±6.45 88.7±1.05 87.9±0.81 90.1±3.63 91.6±0.78 85.6±0.75 92.1±3.81 
Gamma-GT 
(U/l) 
1246.7±68.50 1379.3±54.59 1368.8±33.75 1260.5±28.39 1326.0±42.30 1485.3±59.71 1164.7±31.30 1276.6±81.99 
Triglycerides 
(mg/dl) 
71.5±7.24 80.7±5.62 45.6±4.26 * 40.5±1.09 * 51.5±3.46 * 61.0±2.85 * 48.4±3.64 * 41.5±2.38 * 
Albumin 
(g/dl) 
28.4±1.23 30.9±1.32 28.4±1.41 29.1±0.53 33.3±3.65 36.0±2.50 28.9±1.62 30.2±0.45 
Cholesterol 
(mg/dl) 
169.5±9.80 167.9±5.47 132.0±8.79 * 129.0±5.83* 114.2±2.93 * 122.1±8.15 * 127.5±4.77 * 121.4±9.83 * 
Glucose 
(mg/dl) 
63.8±2.65 70.5±1.97 74.1±6.66 64.5±2.61 69.1±1.87 76.4±3.21 73.2±4.52 76.5±2.42 
Creatinine 
(mg/dl) 
1.5±0.09 1.4±0.16 3.0±0.18 * 3.2±0.24 * 3.1±0.44 * 3.5±0.34 * 1.9±0.19 2.1±0.27 
Values represent the mean±SE of six rats for each group, *P<0.05: Statistically significant from control (Dunnett's test). Subchronic Study (three 
months duration). 
 
Table 2: Subchronic effect of intravenous injection of PEG-Gold NRs (3 mo of dosing cycles) on some serum biochemical parameters in 
rats of both sex (n=10) 
0.9 mg/kg 0.45 mg/kg 0.225 mg/kg Control  
Female Male Female Male Female Male Female Male 
59.4±1.21 60.2±1.33 56.2±1.71 60.7±2.87 57.6±1.44 57.4±1.36 57.8±1.31 58.3±0.67 ALT (U/ml) 
91.9±1.91 91.0±2.16 86.4±1.98 88.9±2.57 86.9±1.35 87.1±1.42 87.8±1.79 86.8±0.84 AST (U/ml) 
1397.8±72.55 1486.7±72.17 1307.1±77.07 1417.2±64.54 1259.5±76.12 1205.6±37.55 1267.5±68.64 1248.5±85.99 Gamma-GT 
(U/l) 
68.4±2.35 67.4±3.39 55.2±3.06 * 58.0±2.94 * 60.8±2.05 * 54.5±2.98 * 72.0±2.80 73.0±3.53 Triglycerides 
(mg/dl) 
28.4±0.65 28.5±0.69 29.7±1.14 28.5±1.59 29.0±1.19 27.1±1.23 29.5±0.69 26.6±0.83 Albumin 
(g/dl) 
170.6±9.67 163.1±3.95 177.0±7.52 171.0±10.91 171.5±4.52 163.4±3.12 175.6±12.73 162.5±5.77 Cholesterol 
(mg/dl) 
66.2±1.30 69.7±3.47 65.4±1.39 65.1±2.54 66.2±1.47 64.3±2.39 70.6±1.88 67.7±2.92 Glucose 
(mg/dl) 
1.4±0.20 1.8±0.22 1.1±0.22 1.5±0.14 1.0±0.14 1.0±0.18 1.3±0.14 1.1±0.36 Creatinine 
(mg/dl) 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test) 
 
Table 3: Subchronic effect of intramuscular injection of PEG-Gold NRs (3 mo of dosing cycles) on some serum biochemical parameters in 
rats of both sex (n=10) 
0.9 mg/kg 0.45 mg/kg 0.225 mg/kg Control  
Female Male Female Male Female Male Female Male 
57.0±0.43 56.5±0.85 54.4±0.47 55.9±0.58 55.1±0.71 55.0±0.39 55.3±0.87 55.0±1.04 ALT (U/ml) 
83.3±1.10 85.0±2.10 81.3±0.70 82.8±0.58 81.6±1.89 84.1±1.75 83.9±1.39 82.1±1.45 AST (U/ml) 
1359.6±57.01 1335.8±69.93 1255.2±30.26 1250.9±32.69 1189.2±23.89 1168.1±28.91 1290.5±52.1 1302.0±34.39 Gamma-GT 
(U/l) 
67.1±2.65 * 74.9±3.44 62.2±3.53 * 69.0±3.10 63.4±1.85 * 71.5±3.94 82.5±2.90 80.4±4.63 Triglycerides 
(mg/dl) 
32.0±1.44 27.8±1.11 28.5±0.54 28.9±0.66 29.6±1.12 30.2±0.99 31.0±1.15 28.4±2.20 Albumin (g/dl) 
160.7±10.21 161.6±3.22 172.3±8.60 171.5±2.26 178.5±7.78 176.6±1.75 165.2±7.27 160.5±7.78 Cholesterol 
(mg/dl) 
62.2±3.75 67.1±3.74 64.7±3.62 69.9±2.48 71.1±1.79 71.9±1.64 69.9±3.95 63.7±4.58 Glucose 
(mg/dl) 
1.4±0.17 0.9±0.25 0.9±0.16 1.1±0.21 0.8±0.18 1.2±0.14 1.4±0.24 0.8±0.17 Creatinine 
(mg/dl) 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test) 
 
Significant decrease of serum triglycerides level was recorded in 
both male and female rats after repeated IV injection of PEG-gold 
NRs for 3 mo, in doses of 0.225 and 0.45 mg/kg compared to control 
rats (table 2). On the other hand, repeated IM injection of PEG-gold 
NRs, in doses of 0.225, 0.45, 0.9 mg/kg respectively, significantly 
lowered serum triglycerides in female rats (table 3).  
While SC injection of PEG-gold NRs resulted in significant decrease 
in serum triglycerides level in both male and female rats after 
repeated injection in all examined dose levels (table 4). 
Chronic toxicity study (six months duration) 
Intravenous injection of PEG-gold NRs for 6 mo resulted in 
significant decrease in serum triglycerides level in rats of both sex, in 
the three examined dose levels. On the other hand, serum creatinine 
level was significantly increased after IV injection of PEG-gold NRs in 
rats of both sex (0.225, 0.45 and 0.9 mg/kg). While, hyponatremia 
(decrease in serum sodium level) was observed in female rats IV-
injected with PEG-gold NRs in doses of 0.45 and 0.9 mg/kg, 
compared to control rats (table ΙΙ in supplementary data). 
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Serum alkaline phosphatase (ALP) was decreased significantly after 
repeated IM injection of PEG-gold NRs with (0.45 and 0.9 mg/kg) in 
rats of both sexes. Moreover, significant decrease in serum 
triglycerides and cholesterol levels was recorded in rats of both sex 
after IM injection with (0.225, 0.45 and 0.9 mg/kg) compared to 
control group rats. Creatinine was significantly lowered in rats after 
IM injection of PEG-gold NRs (0.225, 0.45and 0.9 mg/kg). Serum 
sodium was significantly decreased in female rats injected IM with 
PEG-gold NRs (0.45 and 0.9 mg/kg) and significantly decreased in 
male rats at a dose of 0.225 mg/kg (table ΙΙΙ in supplementary data). 
 
Table 4: Subchronic effect of subcutaneous injection of PEG-Gold NRs (3 mo of dosing cycles) on some serum biochemical parameters in 
rats of both sex (n=10) 
0.9 mg/kg 0.45 mg/kg 0.225 mg/kg Control  
Female Male Female Male Female Male Female Male 
59.4±0.86 60.4±1.33 59.6±0.24 61.6±2.15 60.4±2.35 57.5±0.67 62.6±2.50 58.3±0.72 ALT (U/ml) 
95.5±2.24 91.4±1.23 91.3±2.60 87.3±2.50 93.5±2.63 88.1±1.43 98.7±2.81 89.6±2.68 AST (U/ml) 
1350.5±28.61 1459.5±60.95 1395.7±12.04 1426.3±56.45 1363.9±45.14 1441.8±57.51 1457.4±34.08 1491.8±41.48 Gamma-GT 
(U/l) 
66.3±2.07 * 52.6±3.72 * 64.9±3.16 * 49.9±3.79 * 62.5±4.59 * 53.2±1.68 * 79.4±3.23 73.4±2.22 Triglycerides 
(mg/dl) 
35.8±1.22 33.9±1.02 35.3±1.12 33.4±1.01 34.6±0.49 34.3±0.62 35.3±1.00 31.2±0.43 Albumin 
(g/dl) 
137.8±7.62 146.9±4.82 169.0±9.97 159.4±4.79 170.9±11.63 166.5±9.02 167.4±7.56 170.5±10.17 Cholesterol 
(mg/dl) 
57.9±1.35 57.2±1.11 67.2±1.91 56.7±0.98 65.2±3.63 59.0±2.99 63.8±4.46 62.7±2.64 Glucose 
(mg/dl) 
0.7±0.10 1.6±0.21 0.7±0.11 1.3±0.19 1.3±0.10 1.6±0.11 1.2±0.24 1.0±0.13 Creatinine 
(mg/dl) 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test 
 
Moreover, a significant decrease in serum triglycerides  level was 
recorded in rats of both sex after repeated SC injection of PEG-gold 
NRs for 6 mo with (0.225, 0.45 and 0.9 mg/kg) compared to control 
rats (table ΙV supplementary data). Additionally, hypoglycemia in 
male and female rats injected SC with PEG-gold NRs for 6 mo, at the 
three examined dose levels. Creatinine was significantly increased in 
both male and female rats after SC injection of PEG-gold NRs for 6 
mo, in doses of 0.225 and 0.45 mg/kg, while at dose of 0.9 mg/kg, 
creatinine was significantly decreased. Moreover, slight decrease in 
serum calcium was detected in rats after SC injection of PEG-gold 
NRs in dose of 0.225 mg/kg in male and female rats, and at dose of 
0.45 mg/kg in male rats only. Serum sodium was significantly 
decreased in male and female rats after SC injection of PEG-gold NRs 
(0.9 mg/kg), and in female rats at a dose of 0.45 mg/kg. Serum 
phosphorus was significantly decreased in male rats injected SC with 
PEG-gold NRs, at the three examined dose levels. 
In addition to the obtained findings of biochemical analysis in rats’ 
sera; no detectable abnormal findings following visual observation 
of urine samples and after urine analysis using urinalysis strips in all 
rats of both sex, after repeated IV, IM and SC injection of PEG-gold 
NRs for 6 mo. Calculated red blood cells indices showed significant 
increase in mean corpuscular volume (MCV) and mean corpuscular 
hemoglobin (MCH), following IV injection of PEG-gold NRs for 6 mo 
in female rats in a dose of 0.45 mg/kg. A significant decrease in mean 
corpuscular hemoglobin concentration (MCHC) was found in male 
rats injected IV with PEG-gold NRs in a dose of 0.9 mg/kg (table 5). 
While intramuscular injection of PEG-gold NRs resulted in 
significant increase in MCV in the female rat in a dose of 0.45 mg/kg, 
and in male rats in a dose of 0.9 mg/kg. MCH was significantly 
increased in female rats following IM injection of PEG-gold NRs in a 
dose 0.45 mg/kg (table 6). 
 
Table 5: Chronic effect of intravenous injection of PEG-Gold NRs (6 mo of dosing cycles) on some hematological parameters in rats of both 
sex (n=10) 
0.9 mg/kg 0.45 mg/kg 0.225 mg/kg Control  
Female Male Female Male Female Male Female Male 
8.2±0.46 9.4±0.46 7.6±0.14 8.4±0.62 8.7±0.58 8.2±0.59 7.7±0.19 8.0±0.20 RBC×10[12]/l 
136.4±4.89 139.6±4.20 130.4±2.20 130.3±9.72 139.6±10.17 127.7±6.58 122.5±3.04 119.6±2.58 HGB (g/l) 
45.6±1.59 47.4±1.63 43.5±0.82 44.8±3.22 46.9±3.80 43.3±2.20 40.6±0.95 39.8±0.91 HCT (%) 
53.5±0.93 53.6±0.75 57.0±1.47 * 53.5±1.07 54.0±1.21 53.5±1.50 52.7±0.27 50.0±0.35 MCV (fL) 
15.9±0.25 15.7±0.22 17.0±0.40 * 15.5±0.24 16.0±0.33 15.7±0.45 15.8±0.02 15.0±0.15 MCH (pg) 
298.6±2.23 293.0±1.10 * 299.4±0.93 290.6±3.37 * 297.8±2.42 294.2±0.66 301.3±1.16 300.2±1.07 MCHC (g/l) 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test) 
 
Table 6: Chronic effect of intramuscular injection of PEG-Gold NRs (6 mo of dosing cycles) on some hematological parameters in rats of 
both sex (n=10) 
0.9 mg/kg 0.45 mg/kg 0.225 mg/kg Control  
Female Male Female Male Female Male Female Male 
7.5±0.10 7.9±0.17 7.1±0.04 7.5±0.29 7.3±0.16 7.5±0.15 7.0±0.42 8.1±0.16 RBC×10[12]/l 
119.6±1.25 129.4±3.47 124.6±1.08 121.2±4.33 115.6±3.79 119.3±3.55 115.8±5.63 123.6±2.50 HGB (g/l) 
40.8±0.58 44.1±1.12 42.1±0.43 41.3±1.48 39.4±0.84 40.4±1.12 38.7±1.85 41.7±0.79 HCT (%) 
54.4±0.67 55.9±1.12 * 59.3±0.56 * 55.5±1.59 54.8±0.88 53.8±0.52 55.2±1.35 51.6±0.64 MCV (fL) 
15.9±0.23 16.3±0.37 17.5±0.10 * 16.2±0.43 16.3±0.25 15.8±0.21 16.4±0.30 15.3±0.22 MCH (pg) 
293.0±1.90 293.0±0.63 295.8±1.53 293.2±2.24 298.5±1.47 294.4±0.76 299.2±2.18 296.0±1.18 MCHC (g/l) 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test) 
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Significant decrease in red blood cell count (RBC) was found after SC 
injection of PEG-gold NRs for 6 mo in male rat in a dose of 0.45 mg/kg 
and in male and female rats in a dose of 0.9 mg/kg. While hematocrit 
(HCT) values were significantly increased in female rats injected SC 
with PEG-gold NRs at doses 0.225 and 0.45 mg/kg (table 7). 
Repeated IV or IM injection of PEG-gold NRs in a dose of 0.9 mg/kg 
resulted in significant decrease of total leucocytes count (TLC) in 
male rats. Subcutaneous injection of PEG-gold NRs resulted in 
significant decrease of total leucocytes count (TLC) in male rats at 
the three examined dose levels (table 8).  
Platelets count was significantly decreased in male rats injected IV 
with PEG-gold NRs (0.45 and 0.9 mg/kg), in male rats injected SC 
with PEG-gold NRs in a dose of 0.9 mg/kg (table 9). 
As regard relative organs weight (ROW) there was significant 
increase in liver weight in female rats was detected after repeated IV 
injection of PEG-gold NRs with (0.45 and 0.9 mg/kg) (table V in 
supplementary data). Relative spleen weight was significantly 
decreased in male rats after IM injection of PEG-gold NRs in a dose of 
0.225 mg/kg and in female rats in a dose of 0.45 mg/kg. Moreover, a 
significant decrease in relative epididymis weight after repeated IM 
injection of PEG-gold NRs at the three examined dose levels (table VΙ 
in supplementary data). 
Relative epididymis weight was significant decreased after repeated 
SC injection of PEG-gold NRs in doses of 0.225 and 0.45 mg/kg. 
While the relative uterine weight was significantly increased in a 
dose of 0.9 mg/kg (table VΙΙ in supplementary data). 
A significant decrease was recorded in weight gain of both male and 
female rats after IV injection of PEG-gold NRs for 6 mo in doses of 
0.225 and 0.9 mg/kg. While IM injection with 0.225 and 0.9 mg/kg 
resulted in significant decrease weight gain in female rats. While 
repeated SC injection with 0.225 and 0.9 mg/kg resulted significant 
decrease weight gain of both male and female rats, and in female 
rats at dose of 0.45 mg/kg (table VΙΙΙ in supplementary data). 
 
Table 7: Chronic effect of subcutaneous injection of PEG-Gold NRs (6 mo of dosing cycles) on some hematological parameters in rats of 
both sex (n=10) 
0.9 mg/kg 0.45 mg/kg 0.225 mg/kg Control  
Female Male Female Male Female Male Female Male 
7.0±0.22 * 7.3±0.09 * 7.7±0.12 7.6±0.17 * 7.6±0.19 8.5±0.10 7.3±0.08 8.1±0.19 RBC×10[12]/l 
116.2±1.36 121.2±2.18 130.8±2.06 120.2±3.01 129.4±1.72 136.2±3.93 124.0±2.24 126.6±2.66 HGB (g/l) 
39.7±0.66 40.6±0.67 43.3±0.60 * 42.7±2.12 43.0±0.44 * 45.4±1.30 39.4±0.33 42.6±0.96 HCT (%) 
59.0±1.54 55.6±0.65 56.4±0.91 54.8±1.36 56.9±1.32 53.4±1.09 56.2±1.05 52.4±0.39 MCV (fL) 
17.2±0.39 16.6±0.22 16.9±0.37 15.9±0.39 17.0±0.27 16.0±0.38 16.6±0.34 15.5±0.09 MCH (pg) 
292.6±1.72 298.2±3.84 299.6±1.86 290.7±0.37 300.6±2.25 299.8±2.85 296.8±0.37 297.0±1.58 MCHC (g/l) 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test)Table 8: Chronic effect of 
intravenous, intramuscular and subcutaneous injection of PEG-Gold NRs (6 mo of dosing cycles) on total leucocytes count in rats of both sex (n=10) 
 
Table 8: Chronic effect of intravenous, intramuscular and subcutaneous injection of PEG-Gold NRs (6 months of dosing cycles) on total 
leucocytes count in rats of both sex (n=10) 
 Total leucocytes count (10P9 P/ml) 
IV IM SC 
Male Female Male Female Male Female 
Control  14.4±1.12 8.8±0.26 12.1±0.61 8.2±0.60 14.0±0.28 9.8±0.85 
0.225 mg/kg 14.9±0.40 9.0±0.76 10.7±0.51 7.3±0.67 7.9±0.62* 8.1±0.09* 
0.45 mg/kg 11.8±0.56 10.0±0.48 10.8±1.03 9.0±0.23 11.7±0.39* 7.7±0.61* 
0.9 mg/kg 10.0±0.58 * 8.1±0.42 8.2±0.38* 10.0±1.03 8.7±0.63* 7.6±0.43* 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test) 
 
Table 9: Chronic effect of intravenous, intramuscular and subcutaneous injection of PEG-Gold NRs (6 mo of dosing cycles) on platelets 
count in rats of both sex (n=10) 
  Platelets count (10P9 P/ml)  
IV IM SC 
Male Female Male Female Male Female 
Control  320.8±26.45 292.0±3.10 376.5±10.82 321.8±22.00 399.6±9.97 354.6±10.49 
0.225 mg/kg 271.4±17.41 269.6±21.59 380.4±19.90 326.3±5.62 422.8±10.01 364.2±29.66 
0.45 mg/kg 242.4±15.14 * 280.0±14.24 320.6±24.17 371.8±21.53 427.4±8.08 371.0±17.48 
0.9 mg/kg 184.0±4.30 * 255.6±20.86 412.6±13.81 296.8±24.79 364.4±8.37 * 410.0±28.23 
Values represent the mean±SE of ten rats for each group, * P<0.05: Statistically significant from control (Dunnett's test) 
 
Histopathology 
In the acute toxicity study 
liver tissue of rats injected with single dose of PEG-gold NRs (0.9 
mg/kg) showed mild histopathological changes observed in 
hepatocytes. Only dilated blood sinusoids with mononuclear cellular 
infiltration focal necrosis, apoptosis, intra-nuclear inclusions, 
congested blood vessels and few fibrosis around them were found. 
These changes were prominent in male rats than in female rats’ 
hepatocytes (fig. 3). Spleen tissue showed activation in phagocytes 
that was indicated by its swollen and the dark yellow pigments, 
tingible body macrophages with cytoplasmic engulfed apoptotic 
debris, congestion, heamolized blood and deposition of fibrous 
tissues were scattered through splenic parenchyma (fig. 5). 
While kidneys showed focal histopathological alterations in the form 
of tubular dilatation, some tubules revealed epithelial cell lining with 
pyknotic nuclei and eosinophilic cytoplasm, cellular debris and 
tubular damage (sclerosis) with prominent interstitial congestion. 
The gomeruli showed shrinkage and focal necrosis in intramuscular 
treated male rats (fig. 4). 
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Fig. 3: Photomicrographs of sections in male rat liver injected with single dose of PEG-gold NRs (0.9 mg/kg), (1) intravenously injected 
showing intranuclear inclusions (arrows) and cell necrosis (N). (2) intramuscularly injected showing portal tracts dilatation, congestion, 
edema, perivascular inflammation (Hx&E. X1000, 100) 
 
 
Fig. 4: Photomicrograph of kidney sections of rats injected with single dose of PEG-gold NRs (0.9 mg/kg), (a) female rats (subcutaneously 
injected) showing tubular lumen obliteration, some tubules showed sclerosis, interstitial hemorrhage and inflammatory cells. The 
epithelial cell lining of the deformed tubules are pyknotic. The inset some tubules showed epithelial cell lining with pyknotic nuclei and 
eosinophilic cytoplasm (b) male rats (intramuscularly injected) showing shrinkage and damaged glomeruli (arrow) (Hx&E. X200, 100) 
 
 
Fig. 5: Photomicrographs of spleen sections from rats injected with single dose of PEG-gold NRs (0.9 mg/kg), (a) male rats (intramuscularly 
injected) revealed white and red pulp with deposition of fibrous tissues, white pulp was pale stained due to the presence of macrophage and 
lymphocytes depletion. The inset shows free apoptotic cells and indicates tingible body macrophages with cytoplasmic engulfed apoptotic 
debris. (Hx. E. X100) (b) male rat (intravenously injected) showing different types of parenchyma. The red pulp shows expansion and 
shrinkage of white pulp. The inset shows the apoptotic cells (moth eaten appearance) (Hx&E. X200) 
 
 
Fig. 6: Photomicrographs of liver parenchyma from (a, b) male rats and (c) female rats (subcutaneously injected) with PEG-gold NRs for 
six months showing normal hepatocytes around the central vein and the portal tract with minimal congestion and inflammation in portal 
tracts (Hx&E. X200, 100) 
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In the chronic toxicity study 
Microscopic examination of rat's liver injected IV or SC or IM with 
PEG-gold NRs for six months showed normal hepatocytes with 
minimal hemorrhage and inflammation around blood vessels. No 
significant difference between male and female in the hepatic 
architecture (fig. 6). 
kidneys of rats injected IV or SC or IM with PEG-gold NRs showing 
mild focal histological changes in the form of focal cellular pyknosis 
in some tubular epithelial cells, coagulative necrosis and inter-
tubular hemorrhage (fig. 7). 
While spleen parenchyma of rats (male and female) injected IV or SC 
or IM with PEG-gold NRs showed remarkable changes in female rats 
injected I. V showing enlargement in the red pulp and shrinkage in 
the white pulp (fig. 8). 
Female rats injected I. V with PEG-gold NRs, spleen showed increased 
in macrophages and phagocytosis indicated by hemosiderin pigments. 
While in male there was remarkable congestion in the artery of the 
follicle and swollen reticuloendothelial cells, fibrosis, vacuolation and 
apoptosis in white pulp cells, loosely packed red pulp accompanied by 
hemosiderin pigmentation. Intramuscular injection in female rats 
showed enlargement of the red pulp and destruction of white pulps. 
Increase in fibrous tissues deposition and wide areas of hemorrhage 
and brown pigment deposition. While in males the enlarged white 
pulps and focal hemorrhage in the red pulp. As regard, SC injection in 
female rats showed severe hemorrhage in the red pulps and loosely 
packed white pulp with accumulation of fibrous tissue and showing 
active phagocytosis represented by much dark yellow to brown 
pigments. While in male rats spleen tissue showed enlarged white pulp 
with increased fibrous tissues deposition. White pulps are pale stained 
due to the presence of macrophage and lymphocytes depletion (fig. 8). 
 
 
Fig. 7: Photomicrographs of kidney from (a) male rats and (b) female rats treated (intramuscularly injected) with PEG-gold NRs for six 
months showing few changes in Bowman capsules and tubular epithelial cells in the form of pyknosis (arrows), coagulative necrosis 
(arrow) inter-tubular hemorrhage (Hx&E. X400, 200) 
 
 
Fig. 8: Photomicrographs of spleen parenchyma from (intravenously injected) female rats with PEG-gold NRs for six months (a), showing 
the increased in macrophages and phagocytosis indicated by hemosiderin pigments. (b) male rats, showing congestion in the artery of the 
follicle and swollen reticuloendothelial cells, fibrosis, vacuolation and apoptosis in white pulp cells, loosely packed red pulp accompanied 
by hemosiderin pigmentation (Hx&E. X1000, 400) 
 
DISCUSSION 
Many studies have suggested that gold nanomaterials are bioinert 
and can be used safely. This thought may be due to the established 
safety of bulk gold materials, but as the size decreases into the 
nanoscopic dimensions, gold will behave very differently than in 
bulk. Some researches have found gold to be toxic in the body, where 
elemental gold can undergo oxidation or become soluble by 
cyanidation [4].  
By definition, nanomaterials possess at least one dimension below 
100 nm. Many unique properties of nanomaterials stem from their 
size, nanoparticle sizing is a critical aspect of pre-characterization. 
Additionally, because of intrinsic high dispersion and elevated 
surface energy, nanoparticle aggregation is thought to be common in 
complex experimental conditions such as biological media, although 
surprisingly few studies report much actual aggregation data. At the 
nanoscale, aggregation is extremely difficult to discern, especially in 
biological environment (e. g., serum-containing 50–70 mg/ml of 
protein) but could exert a pronounced effect upon nano-specific 
material properties interacting with cells and tissues [35]. 
The use of polyethylene glycol (PEG) may limit protein adsorption. 
However, tools with which to predict biological responses based on 
the surface properties of nanoparticles are needed. From a nano safety 
perspective, it is important to note that the binding of proteins to 
nanoparticle surfaces not only changes the “identity” and biological 
behavior of the nanoparticle, but the nanoparticle–protein interaction 
will also likely affect the protein due to a disruption of its 
conformational status, which may lead to loss or gain of function [36].  
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Coating of particles with polyethylene glycol results in a prolonged 
circulation time due to the avoidance of macrophage internalization 
of the particles, and this is important to consider when designing 
nanoparticles for targeted drug delivery [37].  
Nanomaterial toxicity can occur through several different mechanisms 
in the body. The main molecular mechanism of nanotoxicity is the 
induction of oxidative stress by free radical formation, which in excess, 
cause damage to biological components through oxidation of lipids, 
proteins, and DNA. Free radicals can originate from several sources 
including phagocytic cell response to the foreign material, insufficient 
amounts of anti-oxidants, presence of transition metals, environmental 
factors, and, physicochemical properties of some nanomaterials. Other 
mechanisms of toxicity from nanomaterials should be considered since 
nanomaterials immediately interact with their surrounding 
environment. When introduced or absorbed into the systemic 
circulation, interaction with blood components can lead to hemolysis 
and thrombosis [4, 38].  
Interestingly, slow clearance and tissue accumulation (storage) of 
potential free radical producing nanomaterials as well as prevalence 
of numerous phagocytic cells in the organs of the reticuloendothelial 
system (RES) makes organs such as the liver and spleen main targets 
of oxidative stress. Additionally, organs of high blood flow that are 
exposed to nanomaterials, such as the kidneys and lungs, can also be 
affected [4]. Normal serum creatinine level in rats is about 0.4-1.4 
mg/dl [39]. In this respect, studies have shown that gold is heavily 
taken up by the kidneys, causing nephrotoxicity, since the gold 
nanoparticle can penetrate into the renal cell [4,40]. This could 
explain the increase in serum creatinine levels in rats injected with 
PEG-Gold NRs for 3 and 6 cycles of dosing in the current study. 
Conversely, serum creatinine will be lower in individuals who have 
undergone loss of muscle mass [41]. 
As regard the decrease in platelets count in rats injected with PEG-
Gold NRs in present study could be attributed to platelet aggregation 
(clumping), which will decrease reported counts since clumps of 
platelets will not be counted with any automated hematology 
analyzers. Radomski et al.[42] investigated the platelet-aggregating 
effects of nanoparticles, both in vitro and in vivo. They cited that, 
nanoparticles resulted in aggregation of human platelets (in vitro 
and amplified the vascular thrombosis in rats (in vivo). 
The white pulp of spleen, located around a central arteriole, is 
composed of the peri arteriolar lymphoid sheath (PALS, T-cell area), 
the adjacent follicles (B-cell area), and marginal zone (B-cell area). 
Decreased cellularity of the PALS region can occur after exposure to 
irradiation, viruses or drugs that can cause necrosis or apoptosis of 
the T cells. This could explain the obtained histopathological 
findings; red pulp enlarged and shrinkage of white pulp; and the 
decrease in TLC in rats’ whole blood, especially the decrease in the 
lymphocyte count, following injection of gold nanorods.  
Accumulation of iron-positive pigment was found in the red pulp, or 
what is called hemosiderosis, was found in the histopathological 
examination of rats’ spleen following PEG-Gold NRs injection in the 
present study. The presence of hemosiderin pigment in the spleen is 
considered normal. It may arise from normal hemoglobin 
breakdown or to chemically-induced methemoglobinemia or 
autoimmune hemolytic anemia [43].  The decrease in ALP in some 
rat groups injected with PEG-Gold NRs, in the result of this study, 
could be interpreted by the fact of, the decreased food consumption 
and body weight routinely noted in toxicology studies results in 
decreased ALP in rats [44]. 
Owed to the role of the kidney in water and electrolyte 
homeostasis [ 41], the mild disturbance or imbalance of some 
electrolytes detected in rats’ sera following PEG-Gold NRs injection 
in our study could be attributed to the effect on kidney tissue which 
was histo-pathologically supported. Additionally, malnutrition 
accompanied by the decrease in appetite, since gold NRs were 
irritating during injection, resulted in a decrease in weight gain of 
rats and further imbalance in some serum electrolytes.  
Surprisingly, decreased triglycerides levels (hypotriglyceridemia); 
was appeared in rats’ sera after either, single or repeated PEG-Gold 
NRs injection. In this respect, for the first time, Hellstrand et al. [45] 
detected lipids in the biomolecular corona surrounding 
nanoparticles and characterized the lipid binding in vitro. Moreover, 
they suggested that lipid and lipoprotein binding is a general feature 
of nanoparticles under physiological conditions, which makes the 
mechanism of the binding and the implications for nanoparticle fate 
and impacts in vivo important topics for future study.  
CONCLUSION 
Evaluation of acute, subchronic and chronic PEG-Gold NRs toxicities 
in rats after IV or IM or SC injection at 3 dose levels; did not reveal 
any serious side effects. But we recommend IV route of injection for 
further preclinical studies as IM and SC injection of PEG-Gold NRs 
was irritating to rats.  For further clinical studies, we recommend the 
intravenous injection of gold nanorods in dose levels ranging from 
2.5-10 mg/70 Kg man. Additionally, according to the results of acute, 
subchronic and chronic toxicity studies; it is important to assess the 
kidney functions, lipid profile, and complete blood picture, if PEG-
Gold NRs will be injected continued for more than 3 mo.  
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